ENGNenGene Holdings Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $1.91 · now $1.91 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, ENGN has typically landed between $1.27 and $2.80 — a range of −33.3% to +46.6% from the issuance price $1.91.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

696 overlapping 1 month windows · 2023-11-012026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($1.91) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where ENGN has typically landed a month from the 2026-09-16 close of $1.91 — the range is history, not a prediction.

$1.27worst · -33.3%$2.8best · +46.6%
  • now $1.91 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $1.9 (-0.7%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $1.62$2.17
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.27$2.8
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 696 windows spanning 2023-11-01 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2026-05-06−81.4%−83.7%+0.0%
2026-04-20−81.1%−83.1%+3.8%
2026-04-17−81.0%−82.2%+9.7%
3 best
2024-02-13+121.1%+0.0%+121.1%
2024-02-07+117.5%+0.0%+117.5%
2024-02-12+116.1%−1.3%+117.5%

696 overlapping windows · 2023-11-012026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~3 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
67%
−2.9%
n=3
Feb
67%
+28.0%
n=3
Mar
33%
−14.4%
n=3
Apr
33%
−2.3%
n=3
May
0%
−42.2%
n=3
Jun
33%
−1.5%
n=3
Jul
100%
+2.8%
n=3
Aug
67%
−0.6%
n=3
Sep
67%
+15.4%
n=3
Oct
100%
+19.8%
n=2
Nov
50%
+4.8%
n=2
Dec
67%
+3.1%
n=3

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$12$1↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

36 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-16Astley-Sparke PhilipdirectorAward / grant31,00031,000Form 4
2026-06-16BRUNK GERALD AdirectorAward / grant31,00031,000Form 4
2026-06-16Glickman Richard MdirectorAward / grant31,00031,000Form 4
2026-06-16Grossman WilliamdirectorAward / grant31,00031,000Form 4
2026-06-16Grossman WilliamdirectorAward / grant200,000200,000Form 4
2026-06-16HASTINGS PAUL JdirectorAward / grant31,00031,000Form 4
2026-06-16Heffernan Michael ThomasdirectorAward / grant31,00031,000Form 4
2026-06-16Joustra WouterdirectorAward / grant31,00031,000Form 4
2026-06-16Zoth Lota S.directorAward / grant31,00031,000Form 4
2026-01-30Connolly JoanofficerAward / grant195,000195,000Form 4
2026-01-30CHEUNG ANTHONY TZEYEWofficerAward / grant195,000195,000Form 4
2026-01-30Cooper Ronald Harold WilfreddirectorAward / grant801,000801,000Form 4
2026-01-30Nichols Alexander JulianofficerAward / grant195,000195,000Form 4
2026-01-30Boyd Matthew RossofficerAward / grant195,000195,000Form 4
2026-01-30Buck JillofficerAward / grant195,000195,000Form 4
2026-01-30Giguere LeeofficerAward / grant195,000195,000Form 4
2026-01-30Daws D. RyanofficerAward / grant220,000220,000Form 4
2025-09-30Sweiti HusseinofficerAward / grant600,000600,000Form 4
2025-07-08Grossman WilliamdirectorAward / grant45,00045,000Form 4
2025-07-08Buck JillofficerAward / grant100,000100,000Form 4
2025-07-08Heffernan Michael ThomasdirectorAward / grant45,00045,000Form 4
2025-07-08Boyd Matthew RossofficerAward / grant100,000100,000Form 4
2025-07-08Astley-Sparke PhilipdirectorAward / grant45,00045,000Form 4
2025-06-16HASTINGS PAUL JdirectorAward / grant22,50022,500Form 4
2025-06-16Glickman Richard MdirectorAward / grant22,50022,500Form 4
2025-06-16Bos JasperdirectorAward / grant22,50022,500Form 4
2025-06-16Pott AmyofficerAward / grant400,000400,000Form 4
2025-06-16Zoth Lota S.directorAward / grant22,50022,500Form 4
2025-06-16BRUNK GERALD AdirectorAward / grant22,50022,500Form 4
2025-06-16Joustra WouterdirectorAward / grant22,50022,500Form 4
2025-01-29Cooper Ronald Harold WilfreddirectorAward / grant850,000850,000Form 4
2025-01-29Daws D. RyanofficerAward / grant280,000280,000Form 4
2025-01-29CHEUNG ANTHONY TZEYEWofficerAward / grant250,000250,000Form 4
2025-01-29Giguere LeeofficerAward / grant250,000250,000Form 4
2025-01-29Nichols Alexander JulianofficerAward / grant250,000250,000Form 4
2025-01-29Pruthi Raj SomofficerAward / grant280,000280,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.